Structural alterations of the epidermal growth factor receptor gene in human gliomas
- PMID: 1557402
- PMCID: PMC48784
- DOI: 10.1073/pnas.89.7.2965
Structural alterations of the epidermal growth factor receptor gene in human gliomas
Abstract
The epidermal growth factor receptor (EGFR) gene is amplified in 40% of malignant gliomas, and the amplified genes are frequently rearranged. We have characterized the genetic alterations associated with these rearrangements in five malignant gliomas. In one tumor the rearrangement resulted in the deletion of most of the extracytoplasmic domain of the receptor, resulting in a hybrid mRNA between new sequences and the truncated EGFR sequence. The predicted amino acid sequence of the protein from this tumor was remarkably similar to that described for several viral erbB oncogenes. Four other tumors were noted to have internal deletions of the EGFR gene. These rearrangements brought about in-frame deletions affecting either of two cysteine-rich domains in the extracytoplasmic portion of the molecule. The clonal nature of these alterations, and the fact that identical alterations were seen in more than one tumor, suggests a role for these mutant receptor proteins in tumorigenesis. Further, these studies document the existence of tumor-specific cell surface molecules resulting from somatic mutation.
Similar articles
-
Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails.Proc Natl Acad Sci U S A. 1992 May 15;89(10):4309-13. doi: 10.1073/pnas.89.10.4309. Proc Natl Acad Sci U S A. 1992. PMID: 1584765 Free PMC article.
-
Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function.Biochem Biophys Res Commun. 1991 Aug 15;178(3):1413-20. doi: 10.1016/0006-291x(91)91051-d. Biochem Biophys Res Commun. 1991. PMID: 1678600
-
Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas.Proc Natl Acad Sci U S A. 1990 Nov;87(21):8602-6. doi: 10.1073/pnas.87.21.8602. Proc Natl Acad Sci U S A. 1990. PMID: 2236070 Free PMC article.
-
Amplified cellular oncogenes in neoplasms of the human central nervous system.Mutat Res. 1992 May;276(3):299-306. doi: 10.1016/0165-1110(92)90016-3. Mutat Res. 1992. PMID: 1374522 Review.
-
Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications.Cancer Lett. 2001 Jan;162 Suppl:S17-S21. doi: 10.1016/s0304-3835(00)00648-0. Cancer Lett. 2001. PMID: 11164186 Review.
Cited by
-
Targeting drug resistance in glioblastoma (Review).Int J Oncol. 2024 Aug;65(2):80. doi: 10.3892/ijo.2024.5668. Epub 2024 Jul 12. Int J Oncol. 2024. PMID: 38994761 Free PMC article. Review.
-
Mammalian target of rapamycin (mTOR) pathways in neurological diseases.Biomed J. 2013 Mar-Apr;36(2):40-50. doi: 10.4103/2319-4170.110365. Biomed J. 2013. PMID: 23644232 Free PMC article. Review.
-
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours.Nat Rev Clin Oncol. 2023 Jan;20(1):49-62. doi: 10.1038/s41571-022-00704-3. Epub 2022 Nov 23. Nat Rev Clin Oncol. 2023. PMID: 36418477 Free PMC article. Review.
-
iNOS: a potential therapeutic target for malignant glioma.Curr Mol Med. 2013 Sep;13(8):1241-9. doi: 10.2174/1566524011313080002. Curr Mol Med. 2013. PMID: 23590833 Free PMC article. Review.
-
Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors.Proc Natl Acad Sci U S A. 2006 May 16;103(20):7817-22. doi: 10.1073/pnas.0510284103. Epub 2006 May 3. Proc Natl Acad Sci U S A. 2006. PMID: 16672372 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous